AI summary
FDA drug withdrawals are legally complex, making it difficult to remove approved treatments even when safety or efficacy concerns arise.
AI-generated summary. Check the original reporting for context and accuracy.
The FDA wants to pull its approval of a drug. It’s not so easy.
Source excerpt
This is the available feed excerpt, which may be shortened or in the publisher’s original language.
In May 2021, the US Food and Drug Administration released a lengthy briefing document on an experimental medication for a rare autoimmune form of vasculitis that often damages the kidneys and lungs. The agency was on the fence about whether to approve the treatment, and it wanted an independent advisory committee to weigh in. Among the questions at hand: Was the drug meaningfully better than existing therapies? Participants in the study, which had been conducted by the California biotechnology company ChemoCentryx, did appear to have slightly higher rates of symptom remission after one year. But according to the FDA, it was hard to interpret the results because the study’s design had been less than optimal. Some advisory committee members expressed a similar view. The effect of the drug, said one, “is just not well verified by this study.” At the same time, many patients, and some physicians, saw in the data a potentially helpful medication, one that might lessen patients’ reliance on steroids, which are highly effective but often cause severe side effects.Read full article Comments
About priority
An automated sorting aid based on source trust, keywords, and entities, on a scale of 1–12. High: 9–12; medium: 6–8; low: 1–5. It does not measure urgency, verify reporting, or indicate editorial endorsement.